High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21).


Seventeen patients affected by acute myeloid leukemia (AML) with t(8;21) were prospectively programmed to receive three courses of high-dose cytarabine (HDARA-C) as post-remission therapy. The median age was 39 years and in all cases t(8;21) was the only karyotypic abnormality. Complete remission (CR) was achieved in 14 out of 17 cases (82%) and, after… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.